WO2002064593A1 - 2-alkoxyphenyl-substituierte imidazotriazinone - Google Patents
2-alkoxyphenyl-substituierte imidazotriazinone Download PDFInfo
- Publication number
- WO2002064593A1 WO2002064593A1 PCT/EP2002/001100 EP0201100W WO02064593A1 WO 2002064593 A1 WO2002064593 A1 WO 2002064593A1 EP 0201100 W EP0201100 W EP 0201100W WO 02064593 A1 WO02064593 A1 WO 02064593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compounds
- mmol
- compound
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to 2-alkoxyphenyl-substituted. Imidazotriazinones, ner process for their preparation and their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
- WO 94/28902 describes pyrazolopyrimidinones which are suitable for the treatment of impotence.
- WO 99/24433 and WO 99/67244 describe imidazotriazinones which are suitable for the treatment of impotence.
- Cyclic guanosine 3 ', 5'-monophosphate metabolizing phosphodiesterases are PDE-1, 2, 5, 6, 9, 10, 11.
- the compounds according to the invention are potent inhibitors of Phosphodiesterase 5.
- the differentiated expression of the phosphodiesterases in different cells, tissues and organs, as well as the differentiated subcellular localization of these enzymes, in combination with the selective inhibitors according to the invention enable a selective increase in the cGMP_ concentration in specific cells, tissues and organs and thereby enable addressing various processes regulated by cGMP. This is particularly to be expected if the synthesis of cGMP is increased under certain physiological conditions. For example, during sexual stimulation, nitrogen monoxide is released in the vessels of the corpus cavernosum by neuronal means, thereby increasing the synthesis of cGMP. This leads to a strong expansion of the vessels that supply the corpus cavernosum with blood, and thus to an erection. Therefore inhibitors of cGMP metabohsive PDEs should be particularly suitable for the treatment of erectile dysfunction.
- An increase in the cGMP concentration can lead to curative, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilating, natriuretic and diuretic effects and can influence the conduction of excitation in the central nervous system and thus affect memory. It can affect short or long-term modulation of vascular and cardiac inotropy, cardiac rhythm and cardiac conduction (JC Stoclet, T. Keravis, N. Komas and C. Lugnier, Exp. Opin. Invest. Drugs (1995), 4 (11), 1081-1100).
- the present invention relates to the compounds of the general formula (I)
- Physiologically acceptable salts are preferred in the context of the invention.
- Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Salts with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid , Toluenesulfonic acid or naphthalenedisulfonic acid.
- inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid
- organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid
- Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
- sodium, potassium, magnesium or calcium salts and ammonium salts which are derived from ammonia or organic amines, such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, are particularly preferred , Lysine, ethylenediamine or 2-phenylethylamine.
- the compounds according to the invention, in particular the salts can also be present as hydrates. In the context of the invention, hydrates are understood to mean those compounds which contain water in the crystal. Such compounds may contain one or more, typically 1 to 5, equivalents of water. Hydrates can be prepared, for example, by removing the compound in question
- the compounds of the invention can be prepared by using compounds of the formula (II)
- L represents straight-chain or branched alkyl having up to 4 carbon atoms
- organic solvents which do not change under the reaction conditions are suitable as solvents for the individual steps.
- solvents preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethane, trichlorethylene or chlorobenzene Dimethylformamide, hexamethylphosphoric triamide, acetonitrile, Acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the solvents mentioned. Ethanol is particularly preferred for the first step and dichloroethane for the second step.
- the reaction temperature can generally be varied within a substantial range. Generally one works in a range from -20 ° C to 200 ° C, preferably from 0 ° C to 70 ° C.
- the process steps according to the invention are generally carried out at normal pressure. However, it is also possible to carry them out at overpressure or underpressure (e.g. in a range from 0.5 to 5 bar).
- the conversion to the compounds of the general formula (V) takes place in a temperature range from 0 ° C. to room temperature and normal pressure.
- reaction with the corresponding amines is carried out in one of the chlorinated hydrocarbons listed above, preferably in dichloromethane.
- the reaction temperature can generally be varied within a substantial range. Generally one works in a range from -20 ° C to 200 ° C, preferably from 0 ° C to room temperature.
- the reaction is generally carried out at normal pressure. However, it is also possible to carry them out at overpressure or underpressure (e.g. in a range from 0.5 to 5 bar).
- the compounds of formula (II) can be prepared by:
- T represents halogen, preferably chlorine
- organic solvents which do not change under the reaction conditions are suitable as solvents for the individual steps of the process.
- solvents preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichlorethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric acid triamide, acetonitrile, acetonitrile, acetonitrile, acetonitrile, acetonitrile, acetonitrile, acetonitrile, acetonitrile, acetic acid triamide, dimethyl acetonitrile,
- Suitable bases are generally alkali metal hydrides or alcoholates, such as, for example, sodium hydride or potassium tert-butylate, or cyclic amines, such as, for example, piperidine, pyridine, dimethylaminopyridine or C 1 -C 4 -alkylamines, such as, for example, triethylamine. Triethylamine, pyridine and / or dimethylaminopyridine are preferred.
- the base is generally used in an amount of 1 mol to 4 mol, preferably from 1.2 mol to 3 mol, in each case based on 1 mol of the compound of the formula (X).
- the reaction temperature can generally be varied within a substantial range. Generally one works in a range from -20 ° C to 200 ° C, preferably from 0 ° C to 100 ° C.
- the compound of formula (III) can be prepared by the compound of formula (XI)
- ammonium chloride in toluene and in the presence of trimethylaluminum in hexane in a temperature range from -20 ° C to room temperature, preferably at 0 ° C and normal pressure and the resulting amidine, _ optionally in situ, is reacted with hydrazine hydrate.
- the compounds according to the invention show an unforeseeable, valuable spectrum of pharmacological activity.
- cGMP-metabolizing phosphodiesterase 5 They inhibit cGMP-metabolizing phosphodiesterase 5. This leads to an increase in cGMP.
- the compounds according to the invention enhance the action of substances such as EDRF (Endothelium derived relaxing factor), ANP
- the compounds of the general formula (I) according to the invention are therefore suitable for the prophylaxis and / or treatment of diseases in which an increase in the cGMP concentration is beneficial, i.e. Diseases associated with cGMP-regulated processes (usually simply referred to as 'cGMP-related diseases' in English). These include cardiovascular diseases, diseases of the genitourinary system and cerebrovascular diseases.
- cardiovascular diseases in the context of the present invention includes diseases such as, for example, high blood pressure, pulmonary hypertension, stable and unstable angina, peripheral and cardiac vascular diseases, arrhythmias, thromboembolic diseases and ischemia such as myocardial infarction, stroke, transistor and ischemic attacks, angina pectoris, peripheral circulatory disorders, prevention of restenosis after thrombolysis therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA) and bypass.
- PTA percutaneous transluminal angioplasty
- PTCA percutaneous transluminal coronary angioplasty
- the compounds of the general formula (I) according to the invention can also have significance for cerebrovascular diseases. These include, for example, cerebral ischemia, stroke, reperfusion damage, brain trauma, edema, cerebral thrombosis, dementia, reduced memory and Alzheimer's disease.
- the relaxing effect on smooth muscles makes them suitable for the treatment of motility disorders in the digestive tract such as gastroparesis and diseases of the genitourinary system such as prostate hypertrophy, BPH, incontinence and especially for the treatment of erectile dysfunction and female sexual dysfunction.
- PDE phosphorus diesterases
- the inhibition of phosphodiesterase 5 leads to an increase in the cGMP concentration. This makes the compounds interesting for all therapies in which an increase in the cGMP concentration can be assumed to be beneficial.
- the new active ingredients and their physiologically acceptable salts can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions , using inert, non-toxic, pharmaceutically acceptable carriers or solvents.
- the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
- the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, if appropriate using them of emulsifiers and / or dispersants, where, for example, if water is used as the diluent, organic solvents can optionally be used as auxiliary solvents.
- the application is carried out in the usual way, preferably orally, transdermally or parenterally, for example perlingually, buccally, intravenously, nasally, rectally or by inhalation.
- doses of 0.001 to 50 mg / kg are expediently administered in the case of oral administration.
- parenteral administration e.g. A dose of 0.001 mg / kg - 0.5 mg / kg is advisable via mucous membranes nasally, buccally, or by inhalation.
- the compounds according to the invention are also suitable for use in veterinary medicine.
- the compounds or their non-toxic salts can be administered in a suitable formulation in accordance with general veterinary practices.
- the veterinarian can determine the type of application and the dosage according to the type of animal to be treated. starting compounds
- reaction mixture is refluxed for 3 hours. It is poured onto ice water, extracted three times with ethyl acetate, dried over sodium sulfate and evaporated.
- Example 2 The preparation was carried out analogously to Example 1 from 2.2 g (5.35 mmol) of the sulfonic acid chloride from Example 5A and 3.22 g (53.5 mmol) of ethylenediamine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002564524A JP2004521907A (ja) | 2001-02-15 | 2002-02-04 | 2−アルコキシフェニル置換されたイミダゾトリアジノン |
CA002438113A CA2438113A1 (en) | 2001-02-15 | 2002-02-04 | 2-alkoxyphenyl substituted imidazotriazinones |
EP02710833A EP1368353A1 (de) | 2001-02-15 | 2002-02-04 | 2-alkoxyphenyl-substituierte imidazotriazinone |
US10/467,966 US20060160810A1 (en) | 2001-02-15 | 2002-02-04 | 2-Alkoxyphenyl substituted imidazotriazinones |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10107639A DE10107639A1 (de) | 2001-02-15 | 2001-02-15 | 2-Alkoxyphenyl-substituierte Imidazotriazinone |
DE10107639.8 | 2001-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002064593A1 true WO2002064593A1 (de) | 2002-08-22 |
Family
ID=7674515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/001100 WO2002064593A1 (de) | 2001-02-15 | 2002-02-04 | 2-alkoxyphenyl-substituierte imidazotriazinone |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060160810A1 (de) |
EP (1) | EP1368353A1 (de) |
JP (1) | JP2004521907A (de) |
CA (1) | CA2438113A1 (de) |
DE (1) | DE10107639A1 (de) |
WO (1) | WO2002064593A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003011262A2 (de) * | 2001-07-23 | 2003-02-13 | Bayer Healthcare Ag | Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen |
US6998483B2 (en) * | 2000-12-18 | 2006-02-14 | Bayer Healthcare Aktiengesellschaft | Process for the preparation of sulphonamide-substituted imidazotriazinones |
US7713972B2 (en) | 2003-06-13 | 2010-05-11 | Asubio Pharma Co., Ltd. | Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors |
CN102351862A (zh) * | 2005-02-18 | 2012-02-15 | 表面线段公司 | 药动学改善的化合物 |
CN103374002A (zh) * | 2012-04-19 | 2013-10-30 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-5抑制剂 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100324037A1 (en) * | 2006-08-24 | 2010-12-23 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
CN102382129B (zh) * | 2010-08-19 | 2014-02-26 | 山东轩竹医药科技有限公司 | 螺环取代的磷酸二酯酶抑制剂 |
CN102372730B (zh) * | 2010-08-19 | 2014-03-26 | 山东轩竹医药科技有限公司 | 桥环取代的磷酸二酯酶抑制剂 |
CN103086920A (zh) * | 2011-11-04 | 2013-05-08 | 山东科技大学 | 一种邻乙氧基苯甲脒盐酸盐的新合成方法 |
CN106008524A (zh) * | 2016-06-01 | 2016-10-12 | 合肥创新医药技术有限公司 | 一种伐地那非杂质的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028902A1 (en) * | 1993-06-09 | 1994-12-22 | Pfizer Limited | Pyrazolopyrimidinones for the treatment of impotence |
WO1999024433A1 (de) * | 1997-11-12 | 1999-05-20 | Bayer Aktiengesellschaft | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren |
WO1999067244A1 (de) * | 1998-06-20 | 1999-12-29 | Bayer Aktiengesellschaft | 7-alkyl- und cycloalkyl-substituierte imidazotriazinone |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10063108A1 (de) * | 2000-12-18 | 2002-06-20 | Bayer Ag | Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen |
-
2001
- 2001-02-15 DE DE10107639A patent/DE10107639A1/de not_active Withdrawn
-
2002
- 2002-02-04 EP EP02710833A patent/EP1368353A1/de not_active Withdrawn
- 2002-02-04 CA CA002438113A patent/CA2438113A1/en not_active Abandoned
- 2002-02-04 US US10/467,966 patent/US20060160810A1/en not_active Abandoned
- 2002-02-04 WO PCT/EP2002/001100 patent/WO2002064593A1/de active Application Filing
- 2002-02-04 JP JP2002564524A patent/JP2004521907A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028902A1 (en) * | 1993-06-09 | 1994-12-22 | Pfizer Limited | Pyrazolopyrimidinones for the treatment of impotence |
WO1999024433A1 (de) * | 1997-11-12 | 1999-05-20 | Bayer Aktiengesellschaft | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren |
WO1999067244A1 (de) * | 1998-06-20 | 1999-12-29 | Bayer Aktiengesellschaft | 7-alkyl- und cycloalkyl-substituierte imidazotriazinone |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6998483B2 (en) * | 2000-12-18 | 2006-02-14 | Bayer Healthcare Aktiengesellschaft | Process for the preparation of sulphonamide-substituted imidazotriazinones |
WO2003011262A2 (de) * | 2001-07-23 | 2003-02-13 | Bayer Healthcare Ag | Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen |
WO2003011262A3 (de) * | 2001-07-23 | 2004-05-27 | Bayer Healthcare Ag | Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen |
US6930108B2 (en) | 2001-07-23 | 2005-08-16 | Bayer Healthcare Ag | Use of 2-alkoxyphenol-substituted imidazotriazinones |
EP1733728A2 (de) * | 2001-07-23 | 2006-12-20 | Bayer HealthCare AG | Verwendung von 2-Alkoxphenyl-substituierten Imidazotriazinonen als Phosphodiesterase-Hemmer |
EP1733728A3 (de) * | 2001-07-23 | 2007-03-21 | Bayer HealthCare AG | Verwendung von 2-Alkoxphenyl-substituierten Imidazotriazinonen als Phosphodiesterase-Hemmer |
US7276504B2 (en) | 2001-07-23 | 2007-10-02 | Bayer Healthcare Ag | Use of 2-alkoxyphenyl-substituted imidazotriazinones |
US7713972B2 (en) | 2003-06-13 | 2010-05-11 | Asubio Pharma Co., Ltd. | Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors |
CN102351862A (zh) * | 2005-02-18 | 2012-02-15 | 表面线段公司 | 药动学改善的化合物 |
CN103374002A (zh) * | 2012-04-19 | 2013-10-30 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-5抑制剂 |
CN103374002B (zh) * | 2012-04-19 | 2015-07-15 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-5抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
CA2438113A1 (en) | 2002-08-22 |
DE10107639A1 (de) | 2002-08-22 |
US20060160810A1 (en) | 2006-07-20 |
EP1368353A1 (de) | 2003-12-10 |
JP2004521907A (ja) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1049695B1 (de) | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren | |
WO2001047928A2 (de) | Imidazo 1,3,5 triazinone und ihre verwendung | |
EP1107968B1 (de) | Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on | |
WO1999067244A1 (de) | 7-alkyl- und cycloalkyl-substituierte imidazotriazinone | |
EP1280805B1 (de) | Neue imidazotriazinone und ihre verwendung | |
EP1534713A1 (de) | Alkyl-substituierte pyrazolopyrimidine | |
EP1261609B1 (de) | Triazolotriazinone und ihre verwendung | |
WO2002064593A1 (de) | 2-alkoxyphenyl-substituierte imidazotriazinone | |
DE19838300A1 (de) | 9-Dialkylaminopurinon-derivate | |
WO1998032755A1 (de) | Purindione als phosphodiesterasehemmer | |
DE19812462A1 (de) | 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid | |
US6777416B2 (en) | Isoxazolo pyrimidinones and the use thereof | |
DE60130772T2 (de) | Pyrrolotriazolopyrimidinonderivate | |
DE19750085A1 (de) | 2-Phenyl-substituierte Imidazotriazinone | |
DE19962928A1 (de) | Neue Imidazo[1,3,5]triazinone und ihre Verwendung | |
DE10003323A1 (de) | Neue Imidazo[1,3,5[triazinone und ihre Verwendung | |
DE19962927A1 (de) | Neue Triazolotriazinone und ihre Verwendung | |
DE10003296A1 (de) | Neue Triazolotriazinone und ihre Verwendung | |
DE19962925A1 (de) | Neue Isoxazolopyrimidinone und ihre Verwendung | |
DE10003287A1 (de) | Neue Isoxazolopyrimidinone und ihre Verwendung | |
DE19840289A1 (de) | 2-Phenyl-substituierte Imidazotriazinone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002710833 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2438113 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002564524 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002710833 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006160810 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10467966 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10467966 Country of ref document: US |